8-K: Cigna Group Reports Strong Q1 2024 Results, Raises Full-Year Outlook

The Cigna Group announced strong first quarter 2024 results, driven by growth in both Evernorth and Cigna Healthcare, and increased its full-year earnings outlook.

Summary

• The Cigna Group reported a net loss of $0.3 billion, or $0.97 per share, for the first quarter of 2024, which includes a $1.8 billion non-cash after-tax investment loss related to the impairment of VillageMD equity securities.
• Adjusted income from operations for Q1 2024 was $1.9 billion, or $6.47 per share, compared to $1.6 billion, or $5.41 per share, in Q1 2023.
• Total revenues for the first quarter of 2024 reached $57.3 billion, a 23% increase compared to the same period in 2023.
• The company's full-year 2024 outlook for adjusted income from operations has been raised to at least $28.40 per share.
• Evernorth Health Services saw a 28% increase in adjusted revenues, while Cigna Healthcare's adjusted revenues grew by 4% in Q1 2024.
• The sale of Cigna's Medicare businesses to HCSC is expected to close in the first quarter of 2025.
• The company repurchased 10.1 million shares of common stock for approximately $3.4 billion year-to-date through May 1, 2024.

Sentiment

Score: 8

Explanation: The document presents a generally positive outlook with strong revenue and adjusted income growth, and an increased full-year outlook. However, the net loss due to the VillageMD impairment and the increase in debt-to-capitalization ratio temper the overall sentiment slightly.

Positives

• The company experienced significant revenue growth, with a 23% increase in total revenues compared to the first quarter of 2023.
• Adjusted income from operations saw a substantial 16% increase year-over-year, indicating improved profitability.
• The full-year earnings outlook has been raised, reflecting management's confidence in future performance.
• Evernorth Health Services demonstrated strong growth with a 28% increase in adjusted revenues.
• Cigna Healthcare also showed positive results with a 20% increase in adjusted income from operations.
• The company's share repurchase program is actively reducing the number of outstanding shares.
• The Medical Care Ratio (MCR) for Cigna Healthcare improved, indicating better cost management.
• Total pharmacy customers increased significantly, showing expansion in that area of the business.

Negatives

• The company reported a net loss of $0.3 billion for the first quarter of 2024, primarily due to a $1.8 billion non-cash after-tax investment loss related to VillageMD.
• The debt-to-capitalization ratio increased to 44.3% at March 31, 2024, compared to 40.1% at December 31, 2023.
• The adjusted margin, pre-tax, for Evernorth Health Services decreased to 2.9% from 3.6% in the first quarter of 2023.
• Total medical customers decreased slightly to 19.2 million, driven by a decrease in Individual and Family Plans customers.
• Behavioral Care customers decreased year-over-year due to non-renewal of supplemental coverage contracts.

Risks

• The company faces risks related to potential cyberattacks and data security incidents.
• There are risks associated with the company's use of artificial intelligence and machine learning.
• The company is subject to economic and market conditions, including the risk of a recession.
• The company has significant indebtedness and the potential for further indebtedness in the future.
• The company is exposed to risks related to strategic transactions and the realization of expected benefits.
• The company is subject to substantial government regulation and changes in laws or regulations.
• The company faces risks related to the outcome of litigation, regulatory audits, and investigations.
• The company is exposed to credit risk related to its reinsurers.

Future Outlook

The Cigna Group's outlook for full-year 2024 adjusted revenues is at least $235.0 billion, and the outlook for full-year 2024 consolidated adjusted income from operations is at least $8.065 billion, or at least $28.40 per share. This outlook includes the impact of expected future share repurchases and anticipated 2024 dividends.

Management Comments

• David M. Cordani, chairman and CEO of The Cigna Group, stated that the strong first quarter results reflect the performance of Evernorth and Cigna Healthcare businesses.
• Cordani also mentioned the company's leadership in addressing the evolving needs of those they serve with their differentiated capabilities.
• Cordani noted that the company is pleased to increase its outlook for full-year earnings.

Industry Context

This announcement reflects a trend of health companies focusing on diversified portfolios and cost management. The growth in Evernorth's pharmacy services aligns with the increasing importance of pharmacy benefit management in the healthcare industry. The improved MCR for Cigna Healthcare indicates a focus on controlling medical costs, a key concern for health insurers.

Comparison to Industry Standards

• Cigna's revenue growth of 23% is strong compared to some of its peers in the health insurance and pharmacy benefit management sectors, such as UnitedHealth Group and CVS Health, which have reported more moderate growth rates in recent quarters.
• The adjusted income from operations growth of 16% is also competitive, indicating effective management of costs and revenue streams.
• The MCR of 79.9% for Cigna Healthcare is within the expected range for large health insurers, but the company's ability to improve this ratio is a positive sign.
• The increase in pharmacy customers by 25% is a significant achievement, suggesting Cigna is gaining market share in this area.
• The impairment of VillageMD equity securities is a notable event, and other companies with similar investments in healthcare providers may face similar challenges.

Stakeholder Impact

• Shareholders will be impacted by the net loss in Q1 2024, but the increased full-year outlook and share repurchases are positive.
• Employees may benefit from the company's growth and improved financial performance.
• Customers may see improved services and offerings due to the company's investments in its businesses.
• Suppliers and partners may benefit from the company's increased business activity.
• Creditors may be impacted by the increase in the debt-to-capitalization ratio.

Next Steps

• The company will continue to execute its strategic initiatives.
• The company will continue to monitor and manage its medical costs.
• The company will continue to focus on growing its customer base.
• The company will finalize the sale of its Medicare businesses to HCSC in the first quarter of 2025.
• The company will complete the final settlement under the ASR Agreements in the second quarter of 2024.

Key Dates

Keywords

Cigna, Healthcare, Evernorth, Pharmacy Benefits, Medical Care Ratio, Adjusted Income, Revenue, Share Repurchase, Financial Results, Earnings